A meta-analysis of double-blind, placebo-controlled trials lasting 3 to 12 months in mild cognitive impairment and mild Alzheimer's disease found a small advantage for acetyl-L-carnitine over placebo on clinical and psychometric measures.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Acetyl-L-Carnitine (ALCAR)' with aliases ALCAR, ALC, O-acetyl-L-carnitine, levacecarnine, acetylcarnitine · 2026-09-27 12:04 · somebody
kind set kind set to small_molecule: palette r2 · 2026-09-27 12:04 · somebody
fact added summary: A meta-analysis of double-blind, placebo-controlled trials lasting 3 to 12 months in mild cognitive impairment and mild · 2026-09-27 12:04 · somebody
fact added summary: In a 24-week randomized trial in 409 women receiving taxane chemotherapy for breast cancer, acetyl-L-carnitine did not p · 2026-09-27 12:04 · somebody
citation added pmid 12598816 cited as emerging: Meta-analysis: small effect of acetyl-L-carnitine over placebo in MCI and mild Alzheimer's disease · 2026-09-27 12:04 · somebody
citation added pmid 23733756 cited as emerging: Acetyl-L-carnitine increased taxane-induced neuropathy at 24 weeks in a placebo-controlled trial · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.